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The antithyroid effect of ketoconazole has been reported. The secretion and action of melatonin in the thyroid 
gland are also known. However, the possible effect of melatonin on ketoconazole-induced antithyroid effect 
is unknown. 
Objective 
We sought to investigate the modulatory effect of ketoconazole and/or melatonin on thyroid function in 
female rats. 
Methods 
Groups 1-4 of female rats respectively underwent 14-day treatment with normal saline, 25 mg/kg 
ketoconazole, 4 mg/kg melatonin and 10 mg/kg melatonin. Groups 5 and 6 both received 14-day treatment 
with ketoconazole and were respectively treated with 4 mg/kg melatonin and 10 mg/kg melatonin 
simultaneously. Groups 7 and 8 respectively underwent 14-day pretreatment with 4 mg/kg melatonin and 
10 mg/kg melatonin, followed by 14-day administration of ketoconazole to both groups. Groups 9 and 10 
were both treated with ketoconazole for 14 days, followed by respective 14-day administration of 4 mg/kg 
melatonin and 10 mg/kg melatonin. 
Results 
TSH, T3, T4, and iodine concentrations were increased by separate administration of ketoconazole and either 
dose of melatonin when compared to control. However, pre-treatment or post-treatment of ketoconazole-
treated rats with melatonin abolished the ketoconazole-induced increase in TSH, T3, T4, and iodine while 
co-administration of ketoconazole with melatonin caused no improvement in the ketoconazole-induced 
increase in TSH, T3, and T4 except iodine concentration. 
Conclusion 
Ketoconazole increased thyroid function, which was ameliorated by pre- or post-treatment with melatonin, 
possibly via modulation of the iodination process. 
___________________________________________________________________________ 
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INTRODUCTION 
Ketoconazole is an artificial base broad-spectrum 
antimycotic drug. Ketoconazole was originally 
introduced for clinical treatment of genital 
candidiasis, superficial fungal infections, breast 
cancer, chronic mucocutaneous candidiasis, and 
prostatic carcinoma but also being used in the 
treatment of Cushing syndrome.[1–3] 
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Ketoconazole destroys fungal membrane integrity 
and causes fungal death by inhibiting the 
synthesis of ergosterol from lanosterol through the 
inhibition of 14α-demethylase that is a 
cytochrome P450 enzyme).[4] Ergosterol is a 
fungal cell membrane sterol that serves a similar 
function as cholesterol does in the animal cell 
membranes.[4,5] The 14α-demethylase activity is 
also important in humans as it is involved in the 
formation of cholesterol,[6] and its inhibition 
causes endocrine disruption such as inhibition of 
steroidogenesis.[7,8] Ketoconazole also directly or 
indirectly (via its metabolite, N-deacetyl 
ketoconazole) causes cellular toxicity (especially 
hepatotoxicity) [9,10] that is mediated through 
oxidative stress.[11] 
Ketoconazole was considered by the European 
Medicines Agency to be used in the European 
Union for the treatment of Cushing’s Syndrome in 
patients above 12 years old.[12] The use of 
ketoconazole has been limited due to its toxicity 
despite its importance as an anti-fungal drug and 
a therapy for Cushing’s disease management. 
Ketoconazole has been replaced with newer drugs 
with less toxicity and more effectiveness for the 
management of those diseases.[8,9] Ketoconazole 
is, therefore, an alternative drug that would only 
be prescribed during a special indication that 
must be strictly monitored especially for any 
disruption of liver function.[3,13,14] Since 
oxidative stress is part of the mechanisms by 
which ketoconazole causes toxicity, the possible 
ameliorative effect of antioxidants like melatonin 
in some diseases caused by ketoconazole toxicity 
needs further investigation. 
Melatonin, (N-acetyl-5-methoxy-tryptamine) is a 
neurohormone that has many functions in plants 
and animals.[15] In mammals, melatonin primary 
source is the pineal gland [16] but it is also 
secreted from extrapineal sources including the 
thyroid gland.[17,18] Melatonin functions include 
regulation of chronobiology, oxidative stress, 
mitochondrial homeostasis, apoptosis,[19] 
oncostatic, anti-aging, and immunomodulatory 
activities.[18] 
Melatonin activity has been confirmed in the 
thyroid gland. For instance, melatonin is produced 
by C cells under the influence of thyroid-
stimulating hormone (TSH), while melatonin 
receptor1 (MT1) is present in thyroid follicular 
cells.[17,20] Moreover, several effects of melatonin 
have been reported in the thyroid gland. Some of 
the effects include the protection of thyroid cells 
due to its antioxidant property,[21] reduction in 
the circulating thyroid hormones,[22] inhibition of 
thyroid cell proliferation and thyroid hormone 
synthesis,[23] as well as increased thyroid 
hormones under some condition.[24] Previous 
findings on the effect of ketoconazole on thyroid 
function are contradictory, though the majority of 
studies reported its antithyroid effect.[25,26] 
However, the regulatory effect of melatonin on 
ketoconazole effect(s) in the thyroid gland is not 
yet understood, which is the information this 




Fifty (50) female Wistar rats weighing 160–180 g 
were housed in wooden cages. Before the study 
was commenced, the animals were maintained 
under standardized conditions (50–80% relative 
humidity, 27–30ºC, and 12h light/dark cycle), and 
acclimatized for 3 weeks in the Physiology 
departmental animal house, University of Ilorin. 
The rats had unrestricted access to water and 
standard rodent pelletized diet and were well-
catered following the criteria contained in the 
“Guide for the Care and Use of Laboratory 
Animals”.[27] 
Experimental Design 
All the rats were randomly divided in a blinded 
fashion into 10 groups, each containing 5 rats. All 
the treatments were given via oral gavage and done 
once daily between 8:00 and 10:00 am. 
Groups 1-4 respectively underwent 14-day 
treatment with normal saline, 25 mg/kg 
ketoconazole, 4 mg/kg melatonin and 10 mg/kg 
melatonin. Groups 5 and 6 both received 14-day 
treatment with ketoconazole and were respectively 
treated with 4 mg/kg melatonin and 10 mg/kg 
melatonin simultaneously. Groups 7 and 8 
respectively underwent 14-day pretreatment with 
4 mg/kg melatonin and 10 mg/kg melatonin, 
followed by 14-day administration of ketoconazole 
to both groups. Groups 9 and 10 were both treated 
with ketoconazole for 14 days, followed by 
respective 14-day administration of 4 mg/kg 
melatonin and 10 mg/kg melatonin. 
Determination of Biochemical Parameters 
After 24 hours of the last treatment, the animals 
were anesthetized by exposing them to diethyl 
ether in a plastic container. Thereafter, they were 
dissected, and a blood sample from each animal 
was collected into separate heparinized bottles by 
cardiac puncture. The blood was then spun for 10 
minutes at 4,000 revolutions per minute and the 
supernatant plasma from each centrifuged blood 
was transferred into separate plain bottles and 
stored at 20ºC before assays of TSH, 
triiodothyronine (T3), thyroxine (T4) and iodine 
using kits from Calbiotech (Spring Valley, CA). 
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Estimation of T3, T4, and TSH 
For the assay of T3, 50 µl of the control, specimen, 
and serum reference were added into the 
designated well, followed by 100 µl of T3-enzyme 
conjugate solution and gentle swirling for 20-30 
seconds. For the assay of T4, 25 µl of the 
standards, specimen, and control were added into 
the designated well, followed by the addition of 50 
µl each of the working T4-enzyme conjugates 
solution and T4-antibody-biotin solution to all 
wells. For assay of TSH, 50 µl of TSH standards, 
sample, and control were added into the 
designated wells and 100 µl of the conjugate 
reagent was added. In all the assays, the 
microplate was then incubated for 60 minutes. 
The wells were emptied of the liquid and were 
washed three times with wash buffer, followed by 
blotting on absorbent paper towels. Then, 100 µl 
of 3,3’,5,5’-Tetramethylbenzidine substrate 
solution was added to all wells and the plates were 
then covered and incubated for 15 minutes, 
followed by 50 µl of stop solution and gentle mixing 
for 15-20 seconds. Within 15 minutes of adding 
stop solution, the ELISA reading of the absorbance 
was done at 450 nm. The concentration of T3, T4 
or TSH was extrapolated from the standard curve 
plotted for each of them. 
Iodine assay 
Iodine assay was done with the microplate method 
as described.[28] 
Statistical Analyses 
The Statistical Package for Social Sciences (SPSS) 
version 22.0 (IBM Corporation, Armonk, NY) was 
used to analyze the data, which are expressed as 
mean ±SEM. One-way analysis of variance 
(ANOVA) was used to compare data after which 
post hoc Least Significance Difference (LSD) for 
multiple comparison test was done. Groups that 
received ketoconazole or melatonin only were 
compared to the normal control group that 
received normal saline, while the groups that 
received a combination of ketoconazole and 
melatonin were compared to the one that received 
ketoconazole only; p < 0.05 was considered 
statistically significant. 
RESULTS 
Effect of ketoconazole and/or melatonin on 
plasma thyroid-stimulating hormone (TSH) in 
rats 
The TSH concentration was increased by separate 
administration of ketoconazole (1.16±0.42 µM) 
and either 4 mg/kg (1.17±0.16 µM) or 10 mg/kg 
(1.02±0.12 µM) of melatonin when compared to 
control (0.46±0.05 µM). However, pre-treatment (4 
mg/kg: 0.51±0.14 µM; 10 mg/kg: 0.30±0.04 µM) 
or post-treatment (4 mg/kg: 0.26±0.03 µM; 10 
mg/kg: 0.17±0.08 µM) of ketoconazole-treated rats 
with either dose of melatonin abolished the 
ketoconazole-induced increase in TSH (1.16±0.42 
µM), while simultaneous administration of 
ketoconazole with 4 mg/kg (1.03±0.26 µM) and 10 
mg/kg (0.55±0.21 µM) of melatonin respectively 
caused no change and  an improvement in 
ketoconazole-induced increase in TSH 
concentration (1.16±0.42 µM) (Figure 1). 
 
Effect of ketoconazole and/or melatonin on 
plasma thyroid hormones concentration 
The triiodothyronine (T3) concentration was 
increased by separate administration of either 
ketoconazole (0.74±0.20 ng) or 10 mg/kg 
melatonin (0.66±0.15 ng) but not 4 mg/kg 
melatonin (0.37±0.07 ng) when compared to 
control (0.26±0.04 ng). However, the ketoconazole-
induced increase in T3 was abolished by 
pretreatment (0.34±0.05 ng) or post-treatment 
(0.36±0.07 ng) of ketoconazole-treated rats with 
only 4 mg/kg melatonin. However, simultaneous 
treatment of ketoconazole and 4 mg/kg (0.88±0.15 
ng) or 10 mg/kg (0.82±0.09 ng) of melatonin did 
not affect T3 when compared to rats that received 
ketoconazole only (0.74±0.20 ng) (Figure 2A). 
When compared to control (1.17±0.10 ng), the 
thyroxine (T4) concentration was increased by 
ketoconazole (2.61±0.87 ng), which was abolished 
by post-treatment with 4 mg/kg (1.27±0.13 ng) 
and 10 mg/kg (1.18±0.16 ng) of melatonin. The 
ketoconazole-induced increase in T4 was neither 
affected by simultaneous treatment with 4 mg/kg 
(2.29±0.24 ng) and 10 mg/kg (3.22±0.69 ng) of 
melatonin, nor with pre-treatment with 4 mg/kg 
(2.93±0.33 ng) and 10 mg/kg (3.01±1.10 ng) of 
melatonin (Figure 2B). 
 
Effect of ketoconazole and/or melatonin on 
plasma iodine concentration 
Ketoconazole (60.19±4.62 µg) and 10 mg/kg 
melatonin (66.84±12.36 ng) but not 4 mg/kg 
melatonin (48.09±0.95 µg) increased iodine 
concentration when compared to control 
(38.01±4.24 µg). The ketoconazole-induced 
increase in iodine was abolished by pretreatment 
with 4 mg/kg melatonin (43.12±0.62 µg) and post-
treatment with 10 mg/kg melatonin (33.95±3.43 
µg) but unaffected by simultaneous treatment with 
either 4 mg/kg (67.23±18.56 µg) or 10 mg/kg 
(71.31±2.70 µg) of melatonin (Figure 3). 
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Figure 1. Effect of ketoconazole and/or melatonin on Thyroid Stimulating Hormone (TSH) in rats. 





































































Figure 2. Effect of ketoconazole and/or melatonin on Triiodothyronine (A) and Thyroxine (B) concentrations 
in rats. *p<0.05 vs. control; #p<0.05 vs. ketoconazole. The doses of melatonin are represented as 4 and 10 
below the corresponding bars. 
Rwanda Journal of Medicine and Health Sciences Vol.3 No.1 March 2020 https://dx.doi.org/10.4314/rjmhs.v3i1.2 
7 
 




























Figure3. Effect of ketoconazole and/or melatonin on iodine concentration in rats. 




The effect of Ketoconazole on thyroid hormone 
remains inconclusive, as there were reported 
discrepancies associated with the dose and 
duration of the studies. Shin et al.[29] reported 
decreased and unchanged levels of both thyroid 
hormones (T3 and T4) following administration of 
100 mg/kg/d and 25 mg/kg/d ketoconazole. 
Twice-daily administration of 60 mg/kg 
ketoconazole reduced T3 and T4 at day 15 but 
increased TSH after 30 days in male rats.[26] 
Meanwhile, 600 mg/day ketoconazole did not 
inhibit thyroid function and hormones synthesis, 
as it did not cause any change of thyroid 
hormones and TSH in normal, hypothyroid, and 
thyrotoxic patients.[30] In this study, we observed 
that 14-day treatment with ketoconazole 
increased plasma TSH and both thyroid hormones 
(T3 and T4). 
The activities of thyroid hormones (T4 and T3) are 
known to be determined by three iodothyronine 
deiodinases, which consist of two 5’-deiodinases 
(D1 and D2) and one 5-deiodinase (D3).[31] D1, 
mainly found in tissues like liver, kidney, and 
thyroid, is primarily involved in the conversion 
(activation) of T4 to T3 in circulation,[32] but it can 
also inactivate the T4 by converting it to an 
inactive metabolite called reverse T3 (rT3). The D2 
is found mainly in the pituitary, brain, and brown 
adipose tissue and it is crucial for the local 
conversion of T4 to T3 in the tissues and is more 
efficient in T4-T3 conversion than D1. Both D1 
and D2 can convert the rT3 to 3,5-diiodo-L-
thyronine (T2).[32] D3, mainly found in the brain, 
fetal tissues, and placenta, is important in the 
inactivation of locally and plasma-derived T3 to 
3,5-diiodo-L-thyronine (T2) and prevents T4 
activation to a lesser extent by converting the T4 
to rT3.[31] Thus, the D3 pathway is the 
predominant means for the clearance of plasma 
T3. So, could ketoconazole-induced increase in 
TSH and thyroid hormones be associated with 
modulation of deiodinases? 
Ketoconazole has been reported to inhibit D1 and 
D2, whose activities are also affected by thyroid 
status.[33] For instance, D1-catalyzed conversion 
of T4 to T3 reduces in hypothyroidism and is 
elevated in hyperthyroidism, while D2-catalyzed 
conversion of T4 to T3 increases secondary to the 
decreased levels of free T4 and T3 
(hypothyroidism) but decreases in 
hyperthyroidism.[32] Previous studies have 
reported higher TSH secretion in D2 knockout 
(D2KO) mice than in normal mice.[34] The 
ketoconazole-induced increase in TSH observed in 
this study and others[26,29] can then lead to 
increased thyroid hormones (T4 and T3), which 
can inhibit D2 and further increase the TSH from 
the pituitary. Though we did not determine the 
levels of the deiodinases (which is one of the 
limitations of this study), we speculate that D2 
might have been inhibited by ketoconazole. 
Melatonin has been reported to stimulate the 
expression of thyroglobulin at the levels of mRNA 
and protein. This stimulation is not mediated via 
PAX8, a transcription factor involved in TSH-
mediated increased thyroglobulin expression but 
has been suggested to be a result of the 
oxidoreductive (antioxidant) effect of 
melatonin.[19] Sakamoto et al.[35] reported an 
increase in TSH and TSH-secreting cells in pars 
tuberalis of rats, which correlate with melatonin 
increase. A rise in plasma T3 and T4 have also 
been reported at some hours after melatonin 
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administration.[23] The increase in thyroid 
parameters in our present study agrees with these 
previous reports. 
However, pre-treatment and post-treatment (but 
not simultaneous treatment) of ketoconazole-
treated rats with melatonin showed the 
abolishment of ketoconazole-induced 
thyrotoxicity. Melatonin-induced reduction in 
TSH, T4, and T3 [22] have been widely reported 
and these reductions occurred along with reduced 
thyroid follicle diameter, height, and 
proliferation.[23] In a 54 h tadpole thyroid culture, 
there was reduced T4 during the first 30 h but not 
during the remaining 24 h and there was reduced 
T3 during the first 12 h but the T3 increased above 
control for the remaining period.[23] 
The reduced thyroid parameters in ketoconazole-
administered rats pretreated or post-treated with 
melatonin might result from both drug interaction, 
as ketoconazole has been shown to increase 
tasimelteon (a novel melatonin receptor agonist) 
activity because of its ability to inhibit 
CYP3A4/5.[36] It could also result from 
modulation of iodothyronine deiodinases in the 
brain, thyroid gland and peripheral tissues by 
melatonin,[37] and protective activity of melatonin 
against any oxidative stress [38] that might have 
been induced by ketoconazole. These then suggest 
that melatonin can increase or reduce thyroid 
parameters depending on conditions such as 
duration and time of administration,[39] 
concentration and light/dark cycle,[40] type of the 
animal,[41] and drug-drug interaction. 
In conclusion, pre- or post-treatment with 
melatonin (especially 4 mg/kg) could ameliorate 
the disruption of the hypothalamic-pituitary-
thyroid axis caused by ketoconazole (see graphical 
abstract). Further studies are necessary to 
determine the roles of melatonin on nuclear T3, 
formation and receptor activities of thyrotropin-
releasing hormone (TRH), TSH, T4, and T3; as well 
as on iodothyronine deiodinases levels in the 
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